賽諾菲是一家研發驅動、AI 賦能的生物制藥公司，致力于煥發生命光彩并實現強勁增長。作為改革開放后首批進入中國的跨國企業之一，賽諾菲于1982年便在中國建立了辦公室，目前擁有從研發、生產制造到商業運營的端到端價值鏈，包括3家生產基地和4大研發基地，業務覆蓋制藥和疫苗。賽諾菲與中國同心同行，致力于將創新藥品和疫苗加速引進中國，造福更多中國百姓，也為合作伙伴、社區和員工創造更美好的生活。<\/p> \n

\n \n \n \n \n \n \n \n \n \n
<optgroup id="kgssg"></optgroup>
<center id="kgssg"></center>
久久久亚洲欧洲日产国码二区

[1] Wang C, et al. Lancet 2018;391(10131):1706-17.<\/span><\/p> <\/td> \n <\/tr> \n

[2] Li M, et al. BMJ Open Respir Res. 2023 Jul;10(1):e001698<\/span><\/p> <\/td> \n <\/tr> \n

[3] 康健,文富強. 從醫保數據分析中國慢性阻塞性肺疾病管理的不足[J]. 中華結核和呼吸雜志,2017,40(12)：884-886.DOI:10.3760\/cma.j.issn.1001-0939.2017.12.002<\/span><\/p> <\/td> \n <\/tr> \n

[4] Int J Chron Obstruct Pulmon Dis. 2022 Mar 3;17:427–437. doi: 10.2147\/COPD.S346591<\/span><\/p> <\/td> \n <\/tr> \n

[5] Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for Prevention, Diagnosis and Management of COPD: 2026 Report. 2025.<\/span><\/p> <\/td> \n <\/tr> \n

[6] Collaborators G B D I. Mortality, morbidity, and hospitalisations due to influenza lower respiratory tract infections, 2017: an analysis for the Global Burden of Disease Study 2017 [J]. Lancet Respir Med, 2019, 7(1): 69-89. DOI:10.1016\/S2213-2600(18)30496-X.<\/span><\/p> <\/td> \n <\/tr> \n

[7] 國家免疫規劃技術工作組流感疫苗工作組. 中國流感疫苗預防接種技術指南（2026-2027）[J]. 中華流行病學雜志, 2023, 44(10): 1507-1530. DOI: 10.3760\/cma.j.cn112338-20230908-00139.<\/span><\/p> <\/td> \n <\/tr> \n <\/tbody> \n <\/table> \n<\/div> \n
<\/p> \n
<\/p> \n
\n<\/div>"]; $("#dvExtra").html(content_array[0]);})();
<center id="kgssg"></center>